Brief: First Patient Dosed In Intelgenx's Resumed 'Buena' Montelukast Versafilm® Phase 2A Trial In Patients With Alzheimer's Disease
20/01/2022 13:25
Jan 20 (Reuters) - Intelgenx Technologies Corp IGX.TO :
* FIRST PATIENT DOSED IN INTELGENX'S RESUMED 'BUENA'
MONTELUKAST
VERSAFILM® PHASE 2A CLINICAL TRIAL IN PATIENTS WITH MILD TO
MODERATE ALZHEIMER'S DISEASE
Source text for Eikon: ID:nGNX5t7qWx
Further company coverage: IGX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA